ViennaLab Diagnostics
ViennaLab Diagnostics specialises in in vitro diagnostic assays for the detection of genetic variants associated with inherited disorders, disease predisposition, pharmacogenetics and oncology. Their portfolio supports the identification of genotype-dependent variability in drug response and toxicity.
ViennaLab RealFast™ assays are based on real-time PCR and detect single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) fast and simply.
CYP2C9 mpx RealFast™ Assay - simultaneous detection of CYP2C9*2 and CYP2C9*3 variants exhibiting impaired enzyme function and response variability to certain anti-coagulants.
HLA-A3101 and HLA-B1502 RealFast™ Assays - discriminate between the presence or absence of these alleles as a tool to prevent hypersensitivity reactions to carbamazepine.
PGX-5FU XL StripAssay® - covers the four most clinically relevant variants in the dihydropyrimidine dehydrogenase (DPYD) gene with therapeutic relevance for fluoropyrimidine treatment as recommended by the European Medicines Agency in April 2020
PGX-CYP2D6 XL StripAssay® in combination with the CYP2D6 RealFastTM CNV Assay detects the most relevant variations (genetic variants as well as copy number changes) of the liver enzyme CYP2D6 in different populations.
Pharmacogenetic testing with ViennaLab assays enables:
- Identification of patients likely to respond to a given therapy
- Detection of reduced or absent drug metabolism capacity
- Assessment of risk for severe or treatment-limiting adverse drug reactions
Please Click Here to visit the ViennaLabs website for their full list of pharmacogenetic assays.